Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial.

CONCLUSIONS: As an add-on to OMT, MUSKARDIA is safe and significantly reduces angina frequency in patients with stable CAD. Moreover, the use of MUSKARDIA is associated with a trend toward reduced MACEs in patients with stable CAD. The results suggest that MUSKARDIA can be used to manage patients with CAD.
TRIAL REGISTRATION: No. ChiCTR-TRC-12003513.
PMID: 33273369 [PubMed - as supplied by publisher]

Source: Chinese Medical Journal - December 2, 2020 Category: General Medicine Authors: Ge JB, Fan WH, Zhou JM, Shi HM, Ji FS, Wu Y, Zhao YL, Qian J, Jin YZ, Liu YW, Wang SH, He SH, Yang P, Wu J, Lu F, Hou ZS Tags: Chin Med J (Engl) Source Type: research